Statistical approaches to evaluate positive control drugs using the hERG assay yielded results aligning with expert assessments, validating the framework for regulatory decision-making.
The proposed statistical framework for evaluating positive control drugs in the hERG assay aligns with expert assessments, supporting its use in regulatory decision-making for proarrhythmia risk.
Absolute Event Rate: 0% vs 0%
Proarrhythmia Assay (CiPA) drugs. The testing results align with the domain experts' assessments, validating the framework's utility for regulatory decision-making.
Weng et al. (Wed,) reported a other. Statistical approaches to evaluate positive control drugs using the hERG assay yielded results aligning with expert assessments, validating the framework for regulatory decision-making.